Background: Myeloid activation contributes to cognitive impairment in chronic human immunodeficiency virus (HIV) infection. We explored whether combination antiretroviral therapy (cART) initiation during acute HIV infection impacts CD163 shedding, a myeloid activation marker, and in turn, implications on the central nervous system (CNS). Methods: We measured soluble CD163 (sCD163) levels in plasma and cerebrospinal fluid (CSF) by enzyme-linked immunosorbent assay in Thais who initiated cART during acute HIV infection (Fiebig stages I-IV). Examination of CNS involvement included neuropsychological testing and analysis of brain metabolites by magnetic resonance spectroscopy. Chronic HIV-infected or uninfected Thais served as controls. Results: We examined 51 adults with acute HIV infection (Fiebig stages I-III; male sex, >90%; age, 31 years). sCD163 levels before and after cART in Fiebig stage I/II were comparable to those in uninfected controls (plasma levels, 97.9 and 93.6 ng/mL, respectively, vs 99.5 ng/mL; CSF levels, 6.7 and 6.4 ng/mL, respectively, vs 7.1 ng/mL). In Fiebig stage III, sCD163 levels were elevated before cART as compared to those in uninfected controls (plasma levels, 135 ng/mL; CSF levels, 10 ng/mL; P < .01 for both comparisons) before normalization after cART (plasma levels, 90.1 ng/mL; CSF levels, 6.5 ng/mL). Before cART, higher sCD163 levels during Fiebig stage III correlated with poor CNS measures (eg, decreased N-acetylaspartate levels), but paradoxically, during Fiebig stage I/II, this association was linked with favorable CNS outcomes (eg, higher neuropsychological test scores). After cART initiation, higher sCD163 levels during Fiebig stage III were associated with negative CNS indices (eg, worse neuropsychological test scores). Conclusion: Initiation of cART early during acute HIV infection (ie, during Fiebig stage I/II) may decrease inflammation, preventing shedding of CD163, which in turn might lower the risk of brain injury.
Background: Myeloid activation contributes to cognitive impairment in chronic human immunodeficiency virus (HIV) infection. We explored whether combination antiretroviral therapy (cART) initiation during acute HIV infection impacts CD163 shedding, a myeloid activation marker, and in turn, implications on the central nervous system (CNS). Methods: We measured soluble CD163 (sCD163) levels in plasma and cerebrospinal fluid (CSF) by enzyme-linked immunosorbent assay in Thais who initiated cART during acute HIV infection (Fiebig stages I-IV). Examination of CNS involvement included neuropsychological testing and analysis of brain metabolites by magnetic resonance spectroscopy. Chronic HIV-infected or uninfected Thais served as controls. Results: We examined 51 adults with acute HIV infection (Fiebig stages I-III; male sex, >90%; age, 31 years). sCD163 levels before and after cART in Fiebig stage I/II were comparable to those in uninfected controls (plasma levels, 97.9 and 93.6 ng/mL, respectively, vs 99.5 ng/mL; CSF levels, 6.7 and 6.4 ng/mL, respectively, vs 7.1 ng/mL). In Fiebig stage III, sCD163 levels were elevated before cART as compared to those in uninfected controls (plasma levels, 135 ng/mL; CSF levels, 10 ng/mL; P < .01 for both comparisons) before normalization after cART (plasma levels, 90.1 ng/mL; CSF levels, 6.5 ng/mL). Before cART, higher sCD163 levels during Fiebig stage III correlated with poor CNS measures (eg, decreased N-acetylaspartate levels), but paradoxically, during Fiebig stage I/II, this association was linked with favorable CNS outcomes (eg, higher neuropsychological test scores). After cART initiation, higher sCD163 levels during Fiebig stage III were associated with negative CNS indices (eg, worse neuropsychological test scores). Conclusion: Initiation of cART early during acute HIV infection (ie, during Fiebig stage I/II) may decrease inflammation, preventing shedding of CD163, which in turn might lower the risk of brain injury.
Authors: Lehn K Weaver; Katharine A Hintz-Goldstein; Patricia A Pioli; Kathleen Wardwell; Nilofer Qureshi; Stefanie N Vogel; Paul M Guyre Journal: J Leukoc Biol Date: 2006-07 Impact factor: 4.962
Authors: T H Sulahian; P Högger; A E Wahner; K Wardwell; N J Goulding; C Sorg; A Droste; M Stehling; P K Wallace; P M Morganelli; P M Guyre Journal: Cytokine Date: 2000-09 Impact factor: 3.861
Authors: Eva-Maria Ratai; Lakshmanan Annamalai; Tricia Burdo; Chan-Gyu Joo; Jeffrey P Bombardier; Robert Fell; Reza Hakimelahi; Julian He; Margaret R Lentz; Jennifer Campbell; Elizabeth Curran; Elkan F Halpern; Eliezer Masliah; Susan V Westmoreland; Kenneth C Williams; R Gilberto González Journal: Magn Reson Med Date: 2011-03-04 Impact factor: 4.668
Authors: Brandon M Imp; Leah H Rubin; Phyllis C Tien; Michael W Plankey; Elizabeth T Golub; Audrey L French; Victor G Valcour Journal: J Infect Dis Date: 2016-10-26 Impact factor: 5.226
Authors: Mona A Mohamed; Margaret R Lentz; Vallent Lee; Elkan F Halpern; Ned Sacktor; Ola Selnes; Peter B Barker; Martin G Pomper Journal: Radiology Date: 2010-02 Impact factor: 11.105
Authors: Shelly J Krebs; Bonnie M Slike; Pasiri Sithinamsuwan; Isabel E Allen; Thep Chalermchai; Somporn Tipsuk; Nittaya Phanuphak; Linda Jagodzinski; Jerome H Kim; Jintanat Ananworanich; Mary A Marovich; Victor G Valcour Journal: AIDS Date: 2016-06-19 Impact factor: 4.177
Authors: Dionna W Williams; Tina M Calderon; Lillie Lopez; Loreto Carvallo-Torres; Peter J Gaskill; Eliseo A Eugenin; Susan Morgello; Joan W Berman Journal: PLoS One Date: 2013-07-26 Impact factor: 3.240
Authors: Thomas A Premeaux; Michelle L D'Antoni; Mohamed Abdel-Mohsen; Satish K Pillai; Kalpana J Kallianpur; Beau K Nakamoto; Melissa Agsalda-Garcia; Bruce Shiramizu; Cecilia M Shikuma; Magnus Gisslén; Richard W Price; Victor Valcour; Lishomwa C Ndhlovu Journal: J Neurovirol Date: 2018-11-26 Impact factor: 2.643
Authors: Sarah F Benki-Nugent; Ira Martopullo; Tony Laboso; Nancy Tamasha; Dalton C Wamalwa; Kenneth Tapia; Agnes Langat; Elizabeth Maleche-Obimbo; Christina M Marra; Paul Bangirana; Michael J Boivin; Grace C John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731
Authors: Leah H Rubin; Deanna Saylor; Gertrude Nakigozi; Noeline Nakasujja; Kevin Robertson; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Sarah M Lofgren; David R Boulware; Raha Dastgheyb; Steven J Reynolds; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Ned Sacktor Journal: J Neurovirol Date: 2019-06-19 Impact factor: 2.643
Authors: Kalei R J Hosaka; Meredith Greene; Thomas A Premeaux; Shireen Javandel; Isabel E Allen; Lishomwa C Ndhlovu; Victor Valcour Journal: J Am Geriatr Soc Date: 2019-06-26 Impact factor: 5.562